GlaxoSmithKline S.A.E

CASE:BIOC Stock Report

Market Cap: ج.م3.2b

GlaxoSmithKlineE Past Earnings Performance

Past criteria checks 2/6

GlaxoSmithKlineE's earnings have been declining at an average annual rate of -15%, while the Pharmaceuticals industry saw earnings growing at 15.1% annually. Revenues have been growing at an average rate of 8.3% per year. GlaxoSmithKlineE's return on equity is 6.2%, and it has net margins of 4.3%.

Key information

-15.0%

Earnings growth rate

-15.0%

EPS growth rate

Pharmaceuticals Industry Growth9.8%
Revenue growth rate8.3%
Return on equity6.2%
Net Margin4.3%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How GlaxoSmithKlineE makes and spends money. Based on latest reported earnings, on an LTM basis.

Earnings and Revenue History

CASE:BIOC Revenue, expenses and earnings (EGP Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 242,8071206130
30 Jun 242,6001335950
31 Mar 242,493384910
31 Dec 232,240603480
30 Sep 232,131-1392850
30 Jun 232,097-1173460
31 Mar 231,914-1203600
31 Dec 221,823-1143380
30 Sep 222,0991933780
30 Jun 221,9591933880
31 Mar 222,0422094330
31 Dec 211,8121554400
30 Sep 211,549-404000
30 Jun 211,627-1043930
31 Mar 211,699-423950
31 Dec 201,993284950
30 Sep 201,9301774990
30 Jun 201,8782305030
31 Mar 201,7641755080
31 Dec 191,7041434740
30 Sep 191,690-134670
30 Jun 191,645194730
31 Mar 191,630324550
31 Dec 181,623504420
30 Sep 181,563-34390
30 Jun 181,556594100
31 Mar 181,5081064080
31 Dec 171,4531023720
30 Sep 171,3501623160
30 Jun 171,2381353040
31 Mar 171,207872670
31 Dec 161,166-42460
30 Sep 161,1162702090
30 Jun 161,0941381780
31 Mar 161,080731860
31 Dec 151,010691830
30 Sep 151,031-961700
30 Jun 151,054-441760
31 Mar 151,031-191650
31 Dec 141,062641710
30 Sep 141,077661970
30 Jun 141,061731920
31 Mar 141,051741980
31 Dec 131,041771920

Quality Earnings: BIOC has a large one-off loss of EGP150.1M impacting its last 12 months of financial results to 30th September, 2024.

Growing Profit Margin: BIOC became profitable in the past.

Free Cash Flow vs Earnings Analysis

Past Earnings Growth Analysis

Earnings Trend: BIOC has become profitable over the past 5 years, growing earnings by -15% per year.

Accelerating Growth: BIOC has become profitable in the last year, making the earnings growth rate difficult to compare to its 5-year average.

Earnings vs Industry: BIOC has become profitable in the last year, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (37.9%).

Return on Equity

High ROE: BIOC's Return on Equity (6.2%) is considered low.

Return on Assets

Return on Capital Employed

Discover strong past performing companies

7D

1Y

7D

1Y

7D

1Y

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/23 18:40
End of Day Share Price 2024/12/23 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

GlaxoSmithKline S.A.E is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution